Werewolf Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity for the and
Condensed Consolidated Statements of Stockholders’ Equity (unaudited)
(amounts in thousands, except share amounts)
| Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance at December 31, 2024 | 44,827,159 | $5 | $487,973 | $(414,588) | $73,390 |
| Stock-based compensation expense | — | — | 2,006 | — | 2,006 |
| Net loss | — | — | — | (18,089) | (18,089) |
| Balance at March 31, 2025 | 44,827,159 | $5 | $489,979 | $(432,677) | $57,307 |
| Common Stock · Additional Paid-in Capital · Accumulated Deficit · Total Stockholders’ Equity | |||||
| Shares · Amount | |||||
| Balance at December 31, 2023 | 39,107,048 | $4 | $455,443 | $(344,073) | $111,374 |
| Issuance of common stock from at the market offering, net of issuance costs of $985 | 4,169,324 | — | 20,089 | — | 20,089 |
| Stock-based compensation expense | — | — | 2,305 | — | 2,305 |
| Stock option exercises | 5,999 | — | 12 | — | 12 |
| Net loss | — | — | — | (16,193) | (16,193) |
| Balance at March 31, 2024 | 43,282,371 | $4 | $477,849 | $(360,266) | $117,587 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.